Method for synthesizing 2-(5-isoxazolyl)-phenol

By treating specific compounds in the presence of an alkali metal base and heating them, combined with hydroxylamine salt and acid treatment, a highly efficient and robust preparation of 2-(5-isoxazolyl)-phenol compounds was achieved, solving the problems of high cost and low efficiency in existing technologies and providing a flexible preparation scheme for commercial scale.

CN114746406BActive Publication Date: 2024-11-01FMC CORP
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202080083676.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-02
Filing Date
2020-12-02
Publication Date
2024-11-01
Estimated Expiration
2040-12-02

AI Technical Summary

Technical Problem

Existing methods for preparing pyrimidinyloxybenzene derivatives suffer from high costs, low efficiency, and inflexible operation on a commercial scale, necessitating lower-cost, more efficient, and more flexible preparation methods.

Method used

A method is employed that involves treating a compound with a specific structure in the presence of an alkali metal base, followed by heating and treatment with hydroxylamine salt and acid, to ultimately prepare a 2-(5-isooxazolyl)-phenol compound, which undergoes a multi-step transformation in a single reactor via a nested reaction.

Benefits of technology

This provides an efficient and robust synthetic route that enables the commercial-scale, low-cost preparation of 2-(5-isooxazolyl)-phenol compounds, simplifying the process and improving preparation efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114746406B_ABST
    Figure CN114746406B_ABST
Patent Text Reader

Abstract

A method for preparing a compound of formula (1) and compounds derived therefrom is disclosed, the method comprising treating a compound of formula (2) to provide a compound of formula (5) and treating the compound of formula (5) with a hydroxylamine salt, wherein R 1 , R 2 and m are as defined in the specification. The compound of formula (1) prepared by the above method can be used to prepare a compound of formula (8), wherein R 1 , R 2 , R 3 and m are as defined in the specification. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a process for preparing 2-(5-isoxazolyl)-phenol and compounds derived therefrom. Background Art

[0002] Methods for preparing certain pyrimidinyloxybenzene derivatives as herbicides are described in WO 2015 / 108779. Methods for preparing pyrimidine derivatives are disclosed in Organic Synthesis 2003, 80, 200-206; Organic Process Research and Development 2005, 9, 141-148 and Eur. J. Org. Chem. 2014, 7426-7432. Although the methods disclosed in the foregoing references can provide the desired compounds, continuous improvements are still sought, particularly in the development of methods for providing materials on a commercial scale. Therefore, there continues to be a need for new methods that are lower cost, more efficient, more flexible, or more convenient to operate. Summary of the invention

[0003] Examples A. The present invention relates to a method for preparing a compound having formula 1,

[0004]

[0005] in

[0006] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0007] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0008] m is 0, 1, 2, or 3;

[0009] The method includes

[0010] The compound having the formula 2

[0011]

[0012] in

[0013] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0014] m is 0, 1, 2 or 3; and

[0015] X is a halogen;

[0016] Using a compound having formula 3

[0017] R 2 (C=O)LG 3

[0019] in

[0020] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0021] LG is chlorine, C1-C4 alkoxy or -O(C=O)R 2

[0022] Treating in the presence of an alkali metal base to provide a compound of formula 4 or an alkali metal salt thereof

[0023]

[0024] in

[0025] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0026] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0027] m is 0, 1, 2 or 3; and

[0028] X is a halogen;

[0029] Heating the compound of formula 4 or its alkali metal salt to provide a compound of formula 5

[0030]

[0031] in

[0032] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0033] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0034] m is 0, 1, 2, or 3;

[0035] The compound of formula 5 is treated with a hydroxylamine salt to provide a compound of formula 6

[0036]

[0037] in

[0038] Each R1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0039] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0040] m is 0, 1, 2, or 3; and

[0041] The compound of formula 6 is treated with an acid.

[0042] Example B. The present invention also relates to a method for preparing a compound having formula 8

[0043]

[0044] in

[0045] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0046] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0047] R 3 is halogen, C1-C4 alkyl or C1-C4 haloalkyl; and

[0048] m is 0, 1, 2, or 3;

[0049] The method includes

[0050] The compound having the formula 2

[0051]

[0052] in

[0053] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0054] m is 0, 1, 2 or 3; and

[0055] X is a halogen;

[0056] Using a compound having formula 3

[0057] R 2 (C=O)LG 3

[0059] in

[0060] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0061] LG is chlorine, C1-C4 alkoxy or -O(C=O)R 2

[0062] Treating in the presence of an alkali metal base to provide a compound of formula 4 or an alkali metal salt thereof

[0063]

[0064] in

[0065] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0066] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0067] m is 0, 1, 2 or 3; and

[0068] X is a halogen;

[0069] Heating the compound of formula 4 or its alkali metal salt to provide a compound of formula 5

[0070]

[0071] in

[0072] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0073] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0074] m is 0, 1, 2, or 3;

[0075] The compound of formula 5 is treated with a hydroxylamine salt to provide a compound of formula 6

[0076]

[0077] in

[0078] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0079] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0080] m is 0, 1, 2, or 3;

[0081] The compound of formula 6 is treated with an acid to provide a compound of formula 1

[0082]

[0083] in

[0084] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0085] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0086] m is 0, 1, 2, or 3; and

[0087] The compound of formula 1 is treated with a compound of formula 7 in the presence of a second base.

[0088]

[0089] in

[0090] Z is halogen or SO2R 4 ;

[0091] R 3 is halogen, C1-C4 alkyl or C1-C4 haloalkyl; and

[0092] R 4 It is a C1-C4 alkyl group.

[0093] Example C. The present invention also relates to a method for preparing a compound having formula 5

[0094]

[0095] in

[0096] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0097] R 2 is C1-C4 haloalkyl; and

[0098] m is 0, 1, 2 or 3; the method comprises

[0099] The compound having the formula 2

[0100]

[0101] in

[0102] Each R 1are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0103] m is 0, 1, 2 or 3; and

[0104] X is a halogen;

[0105] Using a compound having formula 3A

[0106] R 2 (C=O)LG

[0107] 3A

[0108] in

[0109] R 2 is C1-C4 haloalkyl; and

[0110] LG is chlorine, C1-C4 alkoxy or -O(C=O)R 2

[0111] Treating in the presence of an alkali metal base to provide a compound of formula 4 or an alkali metal salt thereof

[0112]

[0113] in

[0114] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0115] R 2 is a C1-C4 haloalkyl group;

[0116] m is 0, 1, 2 or 3; and

[0117] X is halogen; and

[0118] The compound of Formula 4A or an alkali metal salt thereof is heated.

[0119] Example D. The present invention also relates to a compound having formula 5A

[0120]

[0121] in

[0122] R 1 is halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl; and

[0123] R 2 is a C1-C2 haloalkyl group; wherein R 1 When it is fluorine, R 2 Not trifluoromethyl.

[0124] Example E. The present invention also relates to a compound having formula 4A or an alkali metal salt thereof

[0125]

[0126] in

[0127] R 1 is halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0128] R 2 is C1-C2 haloalkyl; and

[0129] X is a halogen; when R 1 When it is fluorine, R 2 Not trifluoromethyl.

[0130] Embodiment F. The method as described in Embodiment B, wherein the compound having Formula 7 is prepared by the following manner:

[0131] The compound having the formula 10

[0132]

[0133] in

[0134] R 3 is halogen, C1-C4 alkyl or C1-C4 haloalkyl; and

[0135] Q is Cl or OH

[0136] Treating in the presence of a halogenating agent and a compound having the formula 11

[0137]

[0138] in

[0139] R A and R B are each independently C1-C4 alkyl; or

[0140] R A and R B Together they are -(CH2)4-, -(CH2)5- or -CH2CH2OCH2CH2-

[0141] To provide an intermediate having formula 12

[0142]

[0143] in

[0144] R 3is halogen, C1-C4 alkyl or C1-C4 haloalkyl; and

[0145] R A and R B are each independently C1-C4 alkyl; or

[0146] R A and R B together are -(CH2)4-, -(CH2)5- or -CH2CH2OCH2CH2-; and

[0147] Hal - is a chloride ion or a bromide ion;

[0148] The intermediate of formula 12 is treated with an acid salt of a compound of formula 13

[0149]

[0150] in

[0151] R 4 Is C1-C4 alkyl

[0152] Treatment in the presence of a base provides a compound of formula 14

[0153]

[0154] in

[0155] R 3 is halogen, C1-C4 alkyl or C1-C4 haloalkyl;

[0156] R 4 is C1-C4 alkyl; and

[0157] The compound of formula 14 is treated with an oxidizing agent. DETAILED DESCRIPTION

[0158] As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having," "contains," "containing," "characterized by," or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation expressly stated. For example, a composition, mixture, process, or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or other elements inherent to such composition, mixture, process, or method.

[0159] The transitional phrase "consisting of" excludes any unrecited element, step, or ingredient. If in a claim, such a phrase will render the claim closed-ended so that it does not include materials other than those recited, except for conventional impurities associated therewith. When the phrase "consisting of" appears in a clause of the body of a claim rather than immediately following the preamble, the phrase is limited only to the elements recited in that clause; other elements are not excluded from the claim as a whole.

[0160] The transitional phrase "consisting essentially of is used to qualify a composition, process, or method that includes materials, steps, features, components, or elements in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristics of the claimed invention. The term "consisting essentially of" is intermediate between "comprising" and "consisting of."

[0161] When the applicant has defined the invention or a portion thereof with open-ended terms such as "comprising," it should be readily understood that (unless otherwise indicated) the specification should be interpreted as also describing the invention using the terms "consisting essentially of" or "consisting of."

[0162] In addition, unless expressly stated to the contrary, "or" refers to an inclusive or rather than an exclusive or. For example, condition A or B is satisfied by any of the following: A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist).

[0163] In addition, the indefinite article "a / an" before an element or component of the present invention is intended to be non-restrictive with respect to the number of instances (i.e., occurrences) of the element or component. Therefore, "a / an" should be understood to include one or at least one, and the singular word form of an element or component also includes the plural, unless the number obviously means the singular.

[0164] As used herein, the term "suitable" means that the entity or condition so described is suitable for the situation or environment represented. As used herein, the term "treatment" or "treating" means using chemicals or chemical processes to change the existing conditions of other materials, chemicals or compounds. The terms "converting", "converted", "conversion" and related words refer to changing an entity such as a compound in structure, form, properties or function. For example, a compound having a first formula or structure is converted into a compound having a second formula or structure by a chemical process involving one or more treatments as defined above.

[0165] As used herein, the term "intermediate" refers to a compound or chemical entity prepared in a step in a chemical process after providing starting materials and before preparing a final product. In some cases, the intermediate is not isolated during the chemical process and is converted to a subsequent compound in situ. A set of brackets surrounding the chemical structure of an intermediate may be used herein to indicate that the intermediate is not isolated before it is converted to a subsequent compound; for example, "[intermediate]".

[0166] As used herein, the term "telescopic" refers to a process in which at least one intermediate compound formed in the process is processed in a subsequent step of the process without its isolation. For example, a compound may be subjected to a series of chemical reactions in only one reactor.

[0167] In the above statements, the term "alkyl", used alone or in compound words such as "alkylthio" or "haloalkyl", includes straight or branched alkyl, such as methyl, ethyl, n-propyl, isopropyl or different butyl, pentyl or hexyl isomers. "Alkenyl" includes straight or branched olefins, such as vinyl, 1-propenyl, 2-propenyl and different butenyl, pentenyl and hexenyl isomers. "Alkenyl" also includes polyenes, such as 1,2-propadienyl and 2,4-hexadienyl. "Alkynyl" includes straight or branched alkynyl, such as ethynyl, 1-propynyl, 2-propynyl and different butynyl, pentynyl and hexynyl isomers.

[0168] "Alkoxy" includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy and different butoxy, pentyloxy and hexyloxy isomers. "Alkoxyalkyl" means alkoxy substitution on an alkyl group. Examples of "alkoxyalkyl" include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2OCH2 and CH3CH2OCH2CH2. "Alkylthio" includes branched or straight chain alkylthio moieties, such as methylthio, ethylthio, and different propylthio, butylthio, pentylthio and hexylthio isomers.

[0169] The term "halogen", alone or in compound words such as "haloalkyl", or when used in descriptions such as "alkyl substituted by halogen", includes fluorine, chlorine, bromine or iodine. In addition, when used in compound words such as "haloalkyl", or when used in descriptions such as "alkyl substituted by halogen", the alkyl group may be partially or completely substituted by halogen atoms (which may be the same or different). Examples of "haloalkyl" or "alkyl substituted by halogen" include CHF2, F3C, ClCH2, CF3CH2 and CF3CCl2.

[0170] The term "haloalkoxy" and the like are defined similarly to the term "haloalkyl". Examples of "haloalkoxy" include CF3O-, CCl3CH2O-, HCF2CH2CH2O-, and CF3CH2O-. "Alkylcarbonyl" refers to a straight or branched alkyl moiety bonded to a C(=O) moiety. Examples of "alkylcarbonyl" include CH3C(=O)-, CH3CH2CH2C(=O)-, and (CH3)2CHC(=O)-. Examples of "alkoxycarbonyl" include CH3OC(=O)-, CH3CH2OC(=O)-, CH3CH2CH2OC(=O)-, (CH3)2CHOC(=O)-, and different butoxycarbonyl or pentyloxycarbonyl isomers. "Alkylcarbonyloxy" refers to a straight or branched alkyl moiety bonded to a C(=O)O- moiety. Examples of "alkylcarbonyloxy" include CH3C(=O)O-, CH3CH2CH2C(=O)O- and (CH3)2CHC(=O)O-.

[0171] The total number of carbon atoms in a substituent group is represented by "C i -C j " prefix represents, wherein, for example, i and j are numbers from 1 to 4. For example, C1-C4 alkylsulfonyl represents methylsulfonyl to butylsulfonyl; C2 alkoxyalkyl represents CH3OCH2-; C3 alkoxyalkyl represents, for example, CH3CH(OCH3)-, CH3OCH2CH2- or CH3CH2OCH2-; and C4 alkoxyalkyl represents various isomers of alkyl substituted with an alkoxy group containing a total of four carbon atoms (examples include CH3CH2CH2OCH2- and CH3CH2OCH2CH2-).

[0172] When a compound is substituted with a substituent having a subscript indicating that the number of said substituents may exceed 1, said substituents (when they exceed 1) are independently selected from the group of substituents defined, (e.g., (R 3 ) m , m is 0, 1, 2 or 3). When a group contains a substituent which may be, for example, hydrogen (when m=0), then when the substituent is hydrogen, it is recognized that this is equivalent to the group being unsubstituted. When a variable group is shown to be optionally attached to a position (e.g., (R 1 ) m ) where m may be 0, then a hydrogen may be present at that position even if not mentioned in the definition of the variable group. When one or more positions on a group are referred to as being "not substituted" or "unsubstituted", then a hydrogen atom is attached to take up any free valences.

[0173] As used herein, the term "optionally" means that optional conditions may or may not be present. For example, when a reaction is optionally carried out in the presence of a solvent, the solvent may or may not be present.

[0174] The term "optionally substituted" refers to a group that is unsubstituted or has at least one non-hydrogen substituent that does not suppress the chemical or biological activity possessed by the unsubstituted analog. As used herein, unless otherwise indicated, the following definitions will apply. The term "optionally substituted" is used interchangeably with the phrase "unsubstituted or substituted" or with the term "(not) substituted". Unless otherwise indicated, the optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of one another.

[0175] Embodiments of the present invention include the following.

[0176] Embodiment A1. The method as described in Embodiment A, wherein each R 1 are independently halogen or cyano.

[0177] Embodiment A2. The method of embodiment A1, wherein each R 1 are independently halogen.

[0178] Embodiment A3. The method of embodiment A2, wherein each R 1 It's chlorine.

[0179] Embodiment A4. The method of embodiment A2, wherein each R 1 It's bromine.

[0180] Embodiment A5. The method of any one of Embodiments A to A4, wherein m is 0, 1 or 2.

[0181] Embodiment A6. The method of Embodiment A5, wherein m is 1 or 2.

[0182] Embodiment A7. The method of embodiment A6, wherein each R 1 Attached to the remainder of Formula 1 at the 3- or 4-position or at both the 3- and 4-positions.

[0183] Embodiment A8. The method of Embodiment A7, wherein m is 1.

[0184] Embodiment A9. The method as described in Embodiment A8, wherein R 1 Attached to the remainder of Formula 1 at the 3-position.

[0185] Embodiment A10. The method of embodiment A8, wherein R 1 Attached to the remainder of Formula 1 at the 4-position.

[0186] Embodiment A11. The method of any one of Embodiments A6 to A10, wherein R 1 It's chlorine.

[0187] Embodiment A12. The method of any one of Embodiments A to A11, wherein R 2 It is a C1-C4 alkyl group or a C1-C4 haloalkyl group.

[0188] Embodiment A13. The method of embodiment A12, wherein R 2 It is a C1-C4 haloalkyl group.

[0189] Embodiment A14. The method of embodiment A13, wherein R 2 It is a C1-C2 fluoroalkyl group.

[0190] Embodiment A15. The method of embodiment A14, wherein R 2 It is a C1 fluoroalkyl group.

[0191] Embodiment A16. The method of embodiment A15, wherein R 2 It is CHF2.

[0192] Embodiment A17. The method of any one of Embodiments A to A16 wherein X is bromine or chlorine.

[0193] Embodiment A18. The method of Embodiment A17 wherein X is chloro.

[0194] Embodiment A19. The method of any one of Embodiments A to A18, wherein the compound of Formula 2 is prepared by:

[0195]

[0196] in

[0197] Each R 1 are independently halogen, C1-C4 alkyl or C1-C4 haloalkyl;

[0198] X is a halogen; and

[0199] m is 0, 1, 2, or 3;

[0200] Treatment is with methylmagnesium halide followed by water or aqueous acid.

[0201] Embodiment A20. The method of embodiment A19, wherein each R 1 are independently halogen.

[0202] Embodiment A21. The method of embodiment A20, wherein each R 1 It's chlorine.

[0203] Embodiment A22. The method of embodiment A20, wherein each R 1 It's bromine.

[0204] Embodiment A23. The method of any one of Embodiments A19 to A22 wherein m is 0, 1 or 2.

[0205] Embodiment A24. The method of Embodiment A23 wherein m is 1 or 2.

[0206] Embodiment A25. The method of embodiment A24, wherein each R 1 Attached to the remainder of Formula 9 at the 2- or 3-position or at both the 2- and 3-positions.

[0207] Embodiment A26. The method of Embodiment A24 wherein m is 1.

[0208] Embodiment A27. The method of embodiment A26, wherein R 1 Attached to the rest of Formula 9 at the 2-position.

[0209] Embodiment A28. The method of embodiment A27, wherein R 1 It's chlorine.

[0210] Embodiment A29. The method of any one of Embodiments A19 to A28 wherein the methylmagnesium halide is methylmagnesium chloride.

[0211] Embodiment A30. The method of any one of Embodiments A to A29, further comprising: reacting a compound having Formula 1 with a compound having Formula 7

[0212]

[0213] in

[0214] Z is halogen or SO2R 4 ;

[0215] R 3 is halogen, C1-C4 alkyl or C1-C4 haloalkyl; and

[0216] R 4 Is C1-C4 alkyl

[0217] Treatment in the presence of a second base provides a compound of formula 8

[0218]

[0219] in

[0220] Each R 1 are independently halogen, cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0221] R 2 is cyano, C1-C4 alkyl or C1-C4 haloalkyl;

[0222] R 3 is halogen, C1-C4 alkyl or C1-C4 haloalkyl; and

[0223] m is 0, 1, 2 or 3.

[0224] Embodiment A31. The method of Embodiment A30 wherein Z is chloro.

[0225] Embodiment A32. The method of Embodiment A30, wherein Z is SO2R 4 .

[0226] Embodiment A33. The method of embodiment A32, wherein R 4 It is a C1-C2 alkyl group.

[0227] Embodiment A34. The method of embodiment A33, wherein R 4 It's methyl.

[0228] Embodiment A35. The method of any one of Embodiments A30 to A34, wherein R 3 It's a halogen.

[0229] Embodiment A36. The method of embodiment A35, wherein R 3 It's chlorine.

[0230] Embodiment A37. The method of any one of Embodiments A30 to A36, wherein the compound of Formula 8 is selected from the group consisting of:

[0231] 2-[2-(3-bromo-5-isoxazolyl)phenoxy]-5-chloropyrimidine,

[0232] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]phenoxy]pyrimidine,

[0233] 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]phenoxy]pyrimidine,

[0234] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine,

[0235] 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine,

[0236] 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine,

[0237] 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine,

[0238] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine,

[0239] 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine,

[0240] 5-bromo-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine and

[0241] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-bromophenoxy]pyrimidine.

[0242] Embodiment A38. The method of A37, wherein the compound of formula 8 is a compound of formula 8A

[0243]

[0244] That is, 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine (alternatively referred to as 5-chloro-2-[3-chloro-2-[3-(difluoromethyl)-5-isoxazolyl]-phenoxy]-pyrimidine; CAS No. 1801862-02-1).

[0245] Embodiment B1. The method as described in Embodiment B, wherein each R 1 are independently halogen or cyano.

[0246] Embodiment B2. The method of embodiment B1, wherein each R 1 are independently halogen.

[0247] Embodiment B3. The method of embodiment B2, wherein each R 1 It's chlorine.

[0248] Embodiment B4. The method as described in Embodiment B3, wherein each R 1 It's bromine.

[0249] Embodiment B5. The method of any one of Embodiments B to B4, wherein m is 0, 1 or 2.

[0250] Embodiment B6. The method of embodiment B5, wherein m is 1 or 2.

[0251] Embodiment B7. The method of embodiment B6, wherein each R 1 Attached to the remainder of Formula 8 at the 3- or 4-position or at both the 3- and 4-positions.

[0252] Embodiment B8. The method of Embodiment B6 wherein m is 1.

[0253] Embodiment B9. The method as described in Embodiment B8, wherein R 1 Attached to the rest of Formula 8 at the 3-position.

[0254] Embodiment B10. The method as described in Embodiment B8, wherein R 1 Attached to the remainder of Formula 1 at the 4-position.

[0255] Embodiment B11. The method of any one of Embodiments B6 to B10, wherein R 1 It's chlorine.

[0256] Embodiment B12. The method of any one of Embodiments B to B11, wherein R 2 It is a C1-C4 alkyl group or a C1-C4 haloalkyl group.

[0257] Embodiment B13. The method of embodiment B12, wherein R 2 It is a C1-C4 haloalkyl group.

[0258] Embodiment B14. The method of embodiment B13, wherein R 2 It is a C1-C2 fluoroalkyl group.

[0259] Embodiment B15. The method of embodiment B14, wherein R 2 It is a C1 fluoroalkyl group.

[0260] Embodiment B16. The method of embodiment B15, wherein R 2 It is CHF2.

[0261] Embodiment B17. The method of any one of Embodiments B to B16 wherein X is bromine or chlorine.

[0262] Embodiment B18. The method of Embodiment B17 wherein X is chloro.

[0263] Embodiment B19. The method of any one of Embodiments B to B18, wherein the compound of Formula 2 is prepared by:

[0264]

[0265] in

[0266] Each R 1 are independently halogen, C1-C4 alkyl or C1-C4 haloalkyl;

[0267] X is a halogen;

[0268] and

[0269] m is 0, 1, 2, or 3;

[0270] Treatment is with methylmagnesium halide followed by water or aqueous acid.

[0271] Embodiment B20. The method of embodiment B19, wherein each R 1 are independently halogen.

[0272] Embodiment B21. The method of embodiment B20, wherein each R 1 It's chlorine.

[0273] Embodiment B22. The method of embodiment B20, wherein each R 1 It's bromine.

[0274] Embodiment B23. The method of any one of Embodiments B19 to B22 wherein m is 0, 1 or 2.

[0275] Embodiment B24. The method of Embodiment B23 wherein m is 1 or 2.

[0276] Embodiment B25. The method of embodiment B24, wherein each R 1 Attached to the remainder of Formula 9 at the 2- or 3-position or at both the 2- and 3-positions.

[0277] Embodiment B26. The method of Embodiment B24 wherein m is 1.

[0278] Embodiment B27. The method of embodiment B26, wherein R 1 Attached to the remainder of Formula 9 at the 2-position.

[0279] Embodiment B28. The method of embodiment B27, wherein R 1 It's chlorine.

[0280] Embodiment B29. The method of any one of Embodiments B19 to B28, wherein the methylmagnesium halide is methylmagnesium chloride.

[0281] Embodiment B30. The method of any one of Embodiments B to B29 wherein Z is chloro.

[0282] Embodiment B31. The method of any one of Embodiments B to B29, wherein Z is SO2R 4 .

[0283] Embodiment B32. The method of embodiment B31, wherein R 4 It is a C1-C2 alkyl group.

[0284] Embodiment B33. The method of embodiment B32, wherein R 4 It's methyl.

[0285] Embodiment B34. The method of any one of Embodiments B to B33, wherein R 3 It's a halogen.

[0286] Embodiment B35. The method of embodiment B34, wherein R 3 It's chlorine.

[0287] Embodiment B36. The method of any one of Embodiments B to B35, wherein the compound of Formula 8 is selected from the group consisting of:

[0288] 2-[2-(3-bromo-5-isoxazolyl)phenoxy]-5-chloropyrimidine,

[0289] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]phenoxy]pyrimidine,

[0290] 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]phenoxy]pyrimidine,

[0291] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine,

[0292] 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine,

[0293] 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine,

[0294] 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine,

[0295] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine,

[0296] 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine,

[0297] 5-bromo-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine and

[0298] 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-bromophenoxy]pyrimidine.

[0299] Embodiment B37. The method of B36, wherein the compound of formula 8 is a compound of formula 8A

[0300]

[0301] That is, 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine (alternatively referred to as 5-chloro-2-[3-chloro-2-[3-(difluoromethyl)-5-isoxazolyl]-phenoxy]-pyrimidine; CAS No. 1801862-02-1).

[0302] Embodiment C1. The method as described in Embodiment C, wherein each R 1 are independently halogen or cyano.

[0303] Embodiment C2. The method of embodiment C, wherein each R 1 are independently halogen.

[0304] Embodiment C3. The method of embodiment C2, wherein each R 1 It's chlorine.

[0305] Embodiment C4. The method of embodiment C2, wherein each R 1 It's bromine.

[0306] Embodiment C5. The method of any one of Embodiments C to C4, wherein m is 0, 1 or 2.

[0307] Embodiment C6. The method of embodiment C5, wherein m is 1 or 2.

[0308] Embodiment C7. The method of embodiment C6, wherein each R 1 Attached to the remainder of Formula 2 at the 2- or 3-position or at both the 2- and 3-positions.

[0309] Embodiment C8. The method of embodiment C6, wherein m is 1.

[0310] Embodiment C9. The method as described in Embodiment C8, wherein R 1 Attached to the remainder of Formula 2 at the 2-position.

[0311] Embodiment C10. The method of embodiment C8, wherein R 1Attached to the remainder of Formula 2 at the 3-position.

[0312] Embodiment C11. The method of any one of embodiments C6 to C10, wherein R 1 It's chlorine.

[0313] Embodiment C12. The method of any one of embodiments C to C11, wherein the compound of formula 2 is prepared by treating a compound of formula 9.

[0314] Embodiment C13. The method of any one of Embodiments C to C13, wherein the compound of Formula 2 is prepared by:

[0315]

[0316] in

[0317] Each R 1 are independently halogen, C1-C4 alkyl or C1-C4 haloalkyl;

[0318] X is a halogen; and

[0319] m is 0, 1, 2, or 3;

[0320] Treatment is with methylmagnesium halide followed by water or aqueous acid.

[0321] Embodiment C14. The method of embodiment C13, wherein each R 1 are independently halogen.

[0322] Embodiment C15. The method of embodiment C14, wherein each R 1 It's chlorine.

[0323] Embodiment C16. The method of embodiment C15, wherein each R 1 It's bromine.

[0324] Embodiment C17. The method of any one of Embodiments C13 to C16, wherein m is 0, 1 or 2.

[0325] Embodiment C18. The method of embodiment C17, wherein m is 1 or 2.

[0326] Embodiment C19. The method of embodiment C18, wherein each R 1 Attached to the remainder of Formula 9 at the 2- or 3-position or at both the 2- and 3-positions.

[0327] Embodiment C20. The method of Embodiment C18 wherein m is 1.

[0328] Embodiment C21. The method of embodiment C20, wherein R 1 Attached to the rest of Formula 9 at the 2-position.

[0329] Embodiment C22. The method of embodiment C21, wherein R 1 It's chlorine.

[0330] Embodiment C23. The method of any one of Embodiments C13 to C22, wherein the methylmagnesium halide is methylmagnesium chloride.

[0331] Embodiment C24. The method as described in Embodiment C, wherein a compound having Formula 5B is prepared

[0332]

[0333] Embodiment D1. A compound as described in Embodiment D, wherein R 1 is halogen or cyano.

[0334] Embodiment D2. The compound as described in Embodiment D1, wherein R 1 It's a halogen.

[0335] Embodiment D3. The compound as described in Embodiment D2, wherein R 1 It's chlorine.

[0336] Embodiment D4. The compound as described in Embodiment D2, wherein R 1 It's bromine.

[0337] Embodiment D5. A compound as described in any one of embodiments D to D4, wherein R 2 It is a C1-C2 fluoroalkyl group.

[0338] Embodiment D6. The compound as described in Embodiment D5, wherein R 2 It is a C1 fluoroalkyl group.

[0339] Embodiment D7. The compound as described in Embodiment D6, wherein R 2 It is CHF2.

[0340] Embodiment D8. The compound as described in Embodiment D7, which is a compound having Formula 5B

[0341]

[0342] Embodiment E1. A compound as described in Embodiment E, wherein R 1 is halogen or cyano.

[0343] Embodiment E2. The compound as described in Embodiment E1, wherein R 1 It's cyano.

[0344] Embodiment E3. The compound as described in Embodiment E1, wherein R 1 It's a halogen.

[0345] Embodiment E4. The compound as described in Embodiment E3, wherein R 1 It's chlorine.

[0346] Embodiment E5. The compound as described in Embodiment E3, wherein R 1 It's bromine.

[0347] Embodiment E6. A compound as described in any one of embodiments E to E5, wherein X is bromo or chloro.

[0348] Embodiment E7. The compound according to Embodiment E6 wherein X is chloro.

[0349] Embodiment E8. A compound as described in any one of Embodiments E to E7, wherein R 2 It is a C1-C2 fluoroalkyl group.

[0350] Embodiment E9. The compound as described in Embodiment E8, wherein R 2 It is a C1 fluoroalkyl group.

[0351] Embodiment E10. The compound as described in Embodiment E9, wherein R 2 It is CHF2.

[0352] Embodiment E11. The compound of any one of Embodiments E to E10 which is a sodium salt, ie, a compound having Formula 4B

[0353]

[0354] Embodiment E12. The compound as described in Embodiment E, which is a compound having Formula 4C or its sodium salt

[0355]

[0356] Embodiment F1. The method as described in Embodiment F, wherein R 4 It is a C1-C2 alkyl group.

[0357] Embodiment F2. The method of embodiment F1, wherein R 4 It's methyl.

[0358] Embodiment F3. The method of any one of Embodiments F to F2, wherein R 3 It's a halogen.

[0359] Embodiment F4. The method of embodiment F3, wherein R 3 It's chlorine.

[0360] Embodiment F5. The method of any one of Embodiments F to F4, wherein the halogenating agent is POCl3.

[0361] Embodiment F5a. The method of Embodiment F5 wherein the halogenating agent is Vilsmeier-Haack reagent.

[0362] Embodiment F6. The method of any one of Embodiments F to F5 wherein Q is Cl.

[0363] Embodiment F7. The method of any one of Embodiments F to FC5 wherein Q is OH.

[0364] Embodiment F8. The method of any one of Embodiments F to F7, wherein R A and R B Each is independently a C1-C4 alkyl group.

[0365] Embodiment F9. The method of embodiment F8, wherein R A and R B Each is independently a C1-C2 alkyl group.

[0366] Embodiment F10. The method of embodiment F9, wherein R A and R B Each is a methyl group.

[0367] Embodiment F11. The method of any one of Embodiments F to F10, wherein the salt of the compound of Formula 13 is a hemisulfate salt.

[0368] Embodiments of the present invention (including the above-mentioned embodiments A to A38, B to B37, C to C24, D to D8, E to E12 and F to F11 and any other embodiments described herein) can be combined in any manner, and the description of the variables in the embodiments not only relates to compounds having formula 8, but also to starting compounds and intermediate compounds having formulas 1 to 7 and 9 to 14 that can be used to prepare compounds having formula 8.

[0369] Preferred embodiments include the following.

[0370] Embodiment P1. The method of Embodiment A, B or F, wherein

[0371] R 2 is C1-C4 haloalkyl; and

[0372] m is 0, 1 or 2.

[0373] Embodiment P2. The method of embodiment P1, wherein

[0374] Each R 1are independently halogen or cyano; and

[0375] R 2 It is a C1-C2 fluoroalkyl group.

[0376] Embodiment P3. The method of embodiment P2, wherein

[0377] R 1 It is a halogen;

[0378] R 2 is a C1 fluoroalkyl group;

[0379] m is 1; and

[0380] R 1 Attached to the remainder of Formula 1 at the 3-position.

[0381] Embodiment P4. The method of embodiment P2, wherein

[0382] R 1 is chlorine; and

[0383] R 2 It is CHF2.

[0384] Embodiment P5. The method of any one of embodiments P1 to P4, wherein R 3 It's chlorine.

[0385] Embodiment P6. The method of any one of Embodiments P1 to P5, wherein Z is chlorine or SO2R 4 .

[0386] Embodiment P7. The method of Embodiment P6 wherein Z is SO2CH3.

[0387] Embodiment P8. A compound as described in Embodiment D or E, wherein R 2 It is a C1-C2 fluoroalkyl group.

[0388] Embodiment P9. The compound as described in Embodiment P8, wherein

[0389] R 1 is a halogen; and

[0390] R 2 It is a C1 fluoroalkyl group.

[0391] Embodiment P10. The compound as described in Embodiment P9, wherein

[0392] R 1 is chlorine; and

[0393] R 2 It is CHF2.

[0394] In the following schemes, unless otherwise indicated, X, R A , R B , R 1 , R 2 , R 3 , R 4 The definitions of and m are as defined above in the description of the summary of the invention and the embodiments.

[0395] The methods described herein provide an efficient and robust synthesis of 2-(isoxazol-5-yl)-phenol of formula 1 that can be used to prepare herbicidal compounds of formula 8. Compounds of formula 1 and 8 have been previously prepared as described in WO 2015 / 108779.

[0396] As shown in Scheme 1, compounds of Formula 1 can be prepared in a telescopic manner, comprising treating 4H-1-benzopyran-4-one of Formula 5 with a hydroxylamine salt, preferably hydroxylamine hydrochloride, in the presence of a base; and treating the resulting 1-(2-hydroxyphenyl)-butane-1,3-dione 3-oxime of Formula 6 with an acid. In some cases, the compound of Formula 6 can be treated with an acid to provide cyclization of the isoxazole to form a compound of Formula 1 without isolation from the reaction mixture.

[0397] Solution 1

[0398]

[0399] The compound of formula 5 is prepared as shown in Scheme 2. The compound of formula 2 is treated with an acylating agent LG(C=O)R of formula 3 in the presence of an alkali metal base. 2 (wherein LG is chloro, alkoxy or -O(C=O)R 2) provides a compound of formula 4 or an alkali metal salt thereof, a compound of formula 4B. Suitable alkali metal bases for the reaction include alkali metal alkoxides such as sodium methoxide, sodium isopropoxide and potassium tert-butoxide; or alkali metal hydroxides such as potassium hydroxide and sodium hydroxide; or alkali metal carbonates and bicarbonates such as sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate and cesium carbonate. The preferred base is sodium methoxide. Suitable solvents include toluene, tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide or N,N-dimethylacetamide. The preferred solvent is N,N-dimethylacetamide. One of ordinary skill in the art will recognize that the compound of formula 4B can exist in more than one tautomeric form, and any tautomeric form of the compound of formula 4B is contemplated by the present invention. For simplicity, only one tautomer is shown. If desired, acidification of the reaction mixture allows separation of the compound of formula 4. Preferably, the compound of formula 4 is not separated because the base promotes the next step.

[0400] The compound of formula 4 or 4B can be cyclized with displacement of the ortho-halogen to provide a compound of formula 5. In some embodiments, the compound of formula 4B is cyclized to a compound of formula 5 under the acylation conditions of the compound of formula 2 and / or by further heating the compound of formula 4B, for example, at a temperature of about 100° C. to 200° C., or about 120° C. to about 180° C., or about 140° C. to about 160° C. In any of such embodiments, the compound of formula 4 or 4B does not need to be isolated. If the compound of formula 4 is isolated from the first reaction mixture, it may be necessary to add a base to promote the cyclization of the compound to the compound of formula 5. Alternatively, the reaction sequence shown in Schemes 1 and 2 can be carried out in a single reactor without isolating the compound of formula 5.

[0401] Solution 2

[0402]

[0403] As shown in Scheme 3, treatment of a nitrile of Formula 9 with a methylmagnesium halide such as methylmagnesium chloride followed by hydrolysis can provide an o-haloacetophenone of Formula 2. Notably, X is chlorine or bromine, and more notably chlorine. In some cases, the compound of Formula 2 may be commercially available.

[0404] Solution 3

[0405]

[0406] As shown in Scheme 4, the present invention also relates to a method for preparing a compound of formula 8 by coupling a pyrimidine of formula 7A or 7B with a phenol of formula 1, typically in the presence of a base and a solvent. Suitable solvents include acetonitrile, toluene, isopropanol, tetrahydrofuran, dimethyl sulfoxide or N,N-dimethylformamide. Suitable bases for the reaction include alkali metal hydrides such as sodium hydride; or alkali metal alkoxides such as sodium isopropoxide and potassium tert-butoxide; or alkali metal hydroxides such as potassium hydroxide and sodium hydroxide; or alkali metal carbonates such as potassium carbonate and cesium carbonate; or amide bases such as lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide and lithium diisopropylamide; or tertiary amines such as triethylamine and diisopropylethylamine. Preferably, the compound of formula 8 can be prepared by nucleophilic substitution with a compound of formula 7A or 7B by heating the compound of formula 1 in the presence of a base such as potassium carbonate or cesium carbonate at a temperature ranging from 20°C to 110°C, or from 50°C to 110°C in a suitable solvent such as acetonitrile or N,N-dimethylformamide.

[0407] Solution 4

[0408]

[0409] As shown in Scheme 5 and Scheme 6, compounds of formula 7B can be prepared in a telescopic manner. The method comprises treating a compound of formula 10 and a compound of formula 11 with a halogenating agent (optionally in a suitable solvent) to provide an intermediate of formula 12, which is treated with an acid salt of a compound of formula 13 in the presence of a base without isolating it to provide a compound of formula 14. A preferred salt of the compound of formula 13 is a hemisulfate salt (Formula 13A shown in Scheme 5). Suitable halogenating agents include POCl3, POBr3, SOCl2, SOBr2, (COCl)2 or COCl2, preferably POCl3, SOCl2, (COCl)2 or COCl2. When a brominating agent is used, Hal in formula 12 - is a bromide ion, and when a chlorinating agent is used, Hal in formula 12 -is a chloride ion. Phosphorus oxychloride (POCl3) is a more preferred halogenating agent. Alternatively, the halogenating agent can be pre-prepared as a Vilsmayer-Hack reagent by the reaction of COCl2 with N,N-dimethylformamide. Suitable solvents include N,N-dimethylformamide, ethylene dichloride, toluene, or acetonitrile. Suitable bases for the reaction include alkali metal alkoxides such as sodium methoxide and sodium isopropoxide; or alkali metal acetates such as sodium acetate and potassium acetate; or tertiary amines such as triethylamine and diisopropylethylamine. N,N-dimethylformamide is a preferred compound of formula 11. In some embodiments, it is worth noting that when the compound of formula 11 is N,N-dimethylformamide, an excess of the compound of formula 11 can be used instead of additional solvent. The compound of formula 10 and the halogenating agent can be added sequentially in any order or added simultaneously to the compound of formula 11.

[0410] Solution 5

[0411]

[0412] As shown in Scheme 6, the alkylsulfonylpyrimidine compound of Formula 7B can be oxidized by using an oxidizing agent such as m-chloroperbenzoic acid, sodium periodate, potassium permanganate, potassium peroxymonosulfate ( ) or hydrogen peroxide) in a suitable solvent or solvent mixture (such as water, dichloromethane, methanol, acetonitrile, acetic acid, or ethyl acetate) to oxidize a compound having formula 14.

[0413] Solution 6

[0414]

[0415] It should be recognized that some of the reagents and reaction conditions described above for preparing compounds with formula 1-14 may not be compatible with certain functional groups present in the intermediate. In these cases, the protection / deprotection sequence or functional group interconversion combined with the synthesis will help to obtain the desired product. The use and selection of protecting groups will be obvious to those skilled in the art of chemical synthesis (see, for example, Greene, TW; Wuts, PGM Protective Groups in Organic Synthesis [protective groups in organic synthesis], 2nd edition; Wiley: New York [Wiley Press, New York], 1991). Those skilled in the art will recognize that in some cases, after introducing a given reagent as described in any individual scheme, it may be necessary to carry out additional conventional synthesis steps not described in detail to complete the synthesis of compounds with formula 1-14. Those skilled in the art will also recognize that it may be necessary to carry out the combination of the steps shown in the above scheme in an order different from the specific sequence presented by the preparation of compounds with formula 1-14. One skilled in the art will also recognize that the compounds of Formulae 1-14 and intermediates described herein can be subjected to a variety of electrophilic, nucleophilic, free radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

[0416] Without further elaboration, it is believed that those skilled in the art can utilize the present invention to the greatest extent using the previous description. Therefore, the following examples should be interpreted as being merely illustrative and not limiting the present disclosure in any way. The steps in the following examples illustrate the procedures for each step in the overall synthetic transformation, and the starting materials for each step do not necessarily have to be prepared by specific preparative experiments whose procedures are described in other examples or steps. Percentages are by weight. The abbreviation "h" stands for "hour" or "hours". "HPLC" means high performance liquid chromatography. 1 H NMR spectra are reported in ppm downfield from tetramethylsilane; s is a singlet, d is a doublet, dd is a doublet of doublets, t is a triplet, and m is a multiplet.

[0417] Synthesis Example 1

[0418] Preparation of 3-chloro-2-[3-(difluoromethyl)isoxazol-5-yl]-phenol

[0419] Step A: Preparation of 5-chloro-2-(difluoromethyl)-4H-1-benzopyran-4-one

[0420] Sodium methoxide (10.8 g, 200 mmol) and N,N-dimethylacetamide (50 mL) were added to a 250-mL round-bottom flask equipped with an overhead stirrer, a distillation head, and a nitrogen inlet at 25 ° C. A premixed solution of 2,6-dichloroacetophenone (35 g, 181 mmol) and ethyl difluoroacetate (27 g, 218 mmol) in N,N-dimethylacetamide (20 mL) was added dropwise to the sodium methoxide slurry to keep the reaction temperature between 25 ° C and 35 ° C. After 1 h at 35 ° C, the methanol and ethanol generated from the reaction were removed by distillation under reduced pressure. N,N-dimethylacetamide (80 mL) was added to a separate 1-L round-bottom flask equipped with an overhead stirrer, a reflux condenser, and a nitrogen inlet, and heated to 150 ° C. The reaction mixture was added to hot N,N-dimethylacetamide within 2.5 h while the temperature was maintained at 150 ° C. Once completed as determined by HPLC analysis, the reaction mixture is cooled to 50 ° C. Water (200 mL) is slowly added to the reactor, and the resulting slurry is slowly cooled to 20 ° C and stirred for 1 h. The solid is then collected by filtration, washed with water (100 mL) and dried at ambient temperature to provide 38 g of crude product. The crude product is treated with activated carbon to remove colored impurities, and recrystallized from toluene to provide 31.7 g of the title compound as a light yellow solid (76% yield of 2,6-dichloroacetophenone). 1 H NMR δ7.79(t,1H),7.70(dd,1H),7.76(dd,1H),7.15-6.89(t,1H),6.68(s,1H). MP=113℃.

[0421] Step B: Preparation of 3-chloro-2-[3-(difluoromethyl)-5-isoxazolyl]-phenol

[0422] 5-chloro-2-(difluoromethyl)-4H-1-benzopyran-4-one (i.e., the product of step A of Synthesis Example 1; 50 g, 217 mmol), hydroxylamine hydrochloride (18.1 g, 260 mmol), and methanol (150 mL) were added to a 500 mL jacketed reactor equipped with an overhead stirrer and a temperature probe at ambient temperature. Solid sodium acetate (21.3 g, 260 mmol) was added to the reaction mixture once, and the resulting slurry was stirred overnight. Then, concentrated hydrogen chloride solution (34 g, 325 mmol) was slowly added, and the resulting slurry was stirred for 1 h. Once completed as determined by HPLC, water (220 mL) was added to the reactor, and the slurry was stirred for 2 h at ambient temperature. The solid was then collected by filtration, washed with 10% methanol in water (150 mL) and dried at ambient temperature to provide 49.1 g of the title compound (93 wt %, 91% yield from 5-chloro-2-(difluoromethyl)-4H-1-benzopyran-4-one). 1 H NMR δ10.7(s,1H),7.48-7.22(t,1H),7.40(t,1H),7.09(d,1H),7.05(s,1H),7.01(d,1H). MP=139.7℃.

[0423] Synthesis Example 2

[0424] Preparation of 5-chloro-2-(methylthio)-pyrimidine (CAS No. 38275-42-2).

[0425] 41 mL of N,N-dimethylformamide was added to a 100 mL jacketed reactor equipped with an overhead stirrer, a thermocouple, a recirculating heating and cooling bath, a nitrogen inlet, and a scrubber, and the reactor was heated to 50 ° C. Chloroacetyl chloride (10 g, 88.5 mmol) was added dropwise, and the reaction mixture was kept at 50 ° C for 1 h. The resulting mixture was then heated to 70 ° C, followed by the dropwise addition of phosphorus oxychloride (13.6 g, 88.5 mmol) to maintain the temperature between 70 ° C and 75 ° C. The reaction was maintained at 70 ° C for 4 h, and then cooled to 50 ° C. S-methylisothiourea hemisulfate (12.3 g, 88.5 mmol) was added to the reaction mixture, followed by the addition of solid sodium methoxide (23.9 g, 443 mmol). The resulting mixture was heated to 60 ° C for 2 h, and then cooled to 40 ° C. Water (60 mL) was added dropwise to the reactor, and the resulting slurry was slowly cooled to 20° C. and stirred for 2 h. The solid was then collected by filtration, washed with water (20 mL) and dried at ambient temperature to provide the title compound (compound of Formula 1) (8.5 g, 60% yield from chloroacetyl chloride). 1H NMR (400MHz, DMSO-d6) δ8.76 (s, 2H), 2.53 (s, 3H). MP=61.6℃.

[0426] Synthesis Example 3

[0427] Alternative preparation of 5-chloro-2-(methylthio)-pyrimidine (CAS No. 38275-42-2)

[0428] To a 100 mL jacketed reactor equipped with an overhead stirrer, thermocouple, recirculating heating and cooling bath, nitrogen inlet, and scrubber was added 12.3 g of Vilsmayer-Hake reagent (92.9 mmol) and 30 mL of N,N-dimethylformamide. The resulting slurry was then heated to 50°C. 10 g of chloroacetyl chloride (88.5 mmol) was added dropwise to maintain the reaction temperature between 50°C and 52°C, and the reaction mixture was maintained at 50°C overnight. The resulting solution was cooled to ambient temperature and transferred to an addition funnel. 17.6 g of triethylamine (177 mmol) and 30 mL of N,N-dimethylformamide were added to the reactor, and the mixture was cooled to 10°C. The solution in the addition funnel was then added dropwise while maintaining the temperature below 25°C, and 13.3 g of S-methylisothiourea hemisulfate (97.4 mmol) was added in one go. The resulting reaction mixture was then heated to 70° C. for 4 h, and cooled to 20° C. Water (100 mL) was added dropwise to the reactor, and the resulting slurry was stirred for 2 h. The solid was then collected by filtration, washed with water (30 mL×2 times), and dried at room temperature to provide 10.1 g of the title product (99.3 wt %, 72% yield from chloroacetyl chloride). 1 H NMR (400MHz, DMSO-d6) δ8.76 (s, 2H), 2.52 (s, 3H). MP=61.6℃.

[0429] Synthesis Example 4

[0430] Preparation of 5-chloro-2-(methylsulfonyl)-pyrimidine (CAS No. 38275-47-7).

[0431] 5-Chloro-2-(methylthio)-pyrimidine (i.e., the product of Synthesis Example 2 or 3; 5 g, 31.1 mmol) and sodium tungstate dihydrate (0.52 g, 1.6 mmol) were added to a 100 mL jacketed reactor equipped with an overhead stirrer, a thermocouple, a recirculating heating and cooling bath, and a nitrogen inlet at ambient temperature, followed by water (15 mL) and ethyl acetate (15 mL). The resulting mixture was heated to 60 ° C, and then 50% aqueous hydrogen peroxide solution (5.3 g, 77.7 mmol) was added dropwise to maintain the reaction temperature between 60 ° C and 65 ° C. After 2 h, the reaction was determined to be complete by HPLC. The reaction mixture was cooled to ambient temperature, and the excess hydrogen peroxide in the reaction mixture was quenched with sodium bisulfite. The organic layer was then separated, and the aqueous layer was extracted with 15 mL of ethyl acetate. The combined organic layers were concentrated to provide a crude product. Crystallization from toluene and heptane provided 5.6 g of the title compound (compound of formula 6) (93% yield from 5-chloro-2-(methylthio)-pyrimidine). 1 H NMR (400MHz, DMSO-d6) δ9.24 (s, 2H), 3.42 (s, 3H). MP=122℃.

[0432] Synthesis Example 5

[0433] 5-Chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]-pyrimidine (alternatively referred to as 5- Preparation of chloro-2-[3-chloro-2-[3-(difluoromethyl)-5-isoxazolyl]-phenoxy]-pyrimidine; CAS No. 1801862-02-1)

[0434] 3-Chloro-2-[3-(difluoromethyl)-5-isoxazolyl]-phenol (i.e., the product of Synthesis Example 1, Step B; 4.02 g, 96.5 wt %, 15.8 mmol), 5-chloro-2-(methylsulfonyl)-pyrimidine (i.e., the product of Synthesis Example 4; 3.44 g, 97.0 wt %, 17.3 mmol), potassium carbonate (3.27 g, 23.7 mmol) and isopropanol (12.1 g) were added to a 100 mL nitrogen-purged glass jacketed reactor equipped with a heating / cooling recirculating bath, a nitrogen inlet, a temperature probe, and an overhead stirrer. The resulting slurry was heated to 65° C. for 1 h, and once completed as judged by HPLC analysis, water (12.1 g) was added over 5 minutes. The reaction mixture was cooled to 54° C., the two liquid phases were separated, and the aqueous phase was removed. Once the organic solution was cooled to 0° C., a solid was crystallized from isopropanol. The solid was collected by filtration, washed with pre-cooled isopropanol / water mixture (4 / 1 v / v, 3.5 g), and dried under vacuum at 60° C. to provide the title compound (4.62 g, 99.4 wt %, 81.2% yield) (compound of Formula 8). 1H NMR (400MHz, CDCl3) δ8.44(s,2H),7.47-7.55(m,2H),7.22(dd,1H),6.61-6.87(t,1H),6.70(s,1H). MP=66.5℃.

[0435] The claimed methods can be used to prepare the following compounds by the procedures described herein together with methods known in the art. The following abbreviations are used in the tables that follow: Et means ethyl (CH2CH3), Pr means propyl, i-Pr means isopropyl, and Bu means butyl.

[0436] Table 1

[0437]

[0438] in

[0439] m is 0 (i.e., R 1 does not exist)

[0440]

[0441]

[0442] Each of the following tables is constructed in the same manner as Table 1 above, except that the header row in Table 1 is replaced with the corresponding header row shown below (i.e., "m is 0 (i.e., R 1 For example, the first entry in Table 2 is a compound having Formula 4, wherein m is 1, R 1 is 3-F, X is Cl and R 2 is CN. The rest of Table 2 is constructed in the same way, and thus the rest of Tables 3 to 59 are constructed in the same way.

[0443]

[0444]

[0445] Table 36

[0446]

[0447] in

[0448] m is 0 (i.e., R 1 does not exist)

[0449]

[0450] Each of the following tables is constructed in the same manner as Table 36 above, except that the header row in Table 36 is replaced with the corresponding header row shown below (i.e., "m is 0 (i.e., R 1 For example, the first entry in Table 37 is a compound having Formula 5, wherein m is 1, R 1 is 5-F and R 2 is CN. The rest of Table 37 is constructed in the same way, and thus the rest of Tables 38 to 70 are constructed in the same way.

[0451]

[0452] Table 71

[0453]

[0454] in

[0455] m is 0 (i.e., R 1 does not exist)

[0456]

[0457] Each of the following tables is constructed in the same manner as Table 71 above, except that the header row in Table 71 is replaced with the corresponding header row shown below (i.e., "m is 0 (i.e., R 1 For example, the first entry in Table 72 is a compound having Formula 1, wherein m is 1, R 1 It is 3-F and R 2 is CN. The rest of Table 72 is constructed in the same way, and thus the rest of Tables 73 to 105 are constructed in the same way.

[0458]

[0459]

[0460] Table 106

[0461]

[0462] in

[0463] m is 0 (i.e., R 1 does not exist)

[0464]

[0465]

[0466] Each of the following tables is constructed in the same manner as Table 106 above, except that the header row in Table 106 is replaced with the corresponding header row shown below (i.e., "m is 0 (i.e., R 1 For example, the first entry in Table 107 is a compound having Formula 8, wherein m is 1, R 1 Yes 3-F, R 2 is CN and R 3 The remainder of Table 107 is constructed in the same manner, and thus the remainder of Tables 108 to 140 are constructed in the same manner.

[0467]

[0468]

Claims

1. A method for preparing a compound having formula 1 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3; The method includes The compound having the formula 2 in Each R 1 are independently halogen; m is 1, 2, or 3; and X is a halogen; Using a compound having formula 3 R 2 (C=O)LG 3 in R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and LG is chlorine, C 1 -C 4 Alkoxy or -O(C=O)R 2 ; Treating in the presence of an alkali metal base to provide a compound of formula 4 or an alkali metal salt thereof in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; m is 1, 2, or 3; and X is a halogen; Heating the compound of formula 4 or its alkali metal salt to provide a compound of formula 5 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3; The compound of formula 5 is treated with a hydroxylamine salt to provide a compound of formula 6 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3; and The compound of formula 6 is treated with an acid.

2. The method according to claim 1, in, R 2 It is C 1 -C 4 haloalkyl; and m is 1 or 2.

3. The method according to claim 2, in, Each R 1 are independently halogen; and R 2 It is C 1 -C 2 Fluoroalkyl.

4. The method according to claim 3, in, R 1 It is a halogen; R 2 It is C 1 Fluoroalkyl; m is 1; and R 1 Attached to the remainder of Formula 1 at the 3-position.

5. The method according to claim 4, in, R 1 is chlorine; and R 2 is CHF 2 .

6. The method according to claim 1, in, The compound of formula 2 is prepared by the following method: a compound of formula 9 in Each R 1 are independently halogen; X is a halogen; and m is 1, 2, or 3; Treatment is with methylmagnesium halide followed by water or aqueous acid.

7. The method of claim 1 further comprises reacting the compound of formula 1 with a compound of formula 7 in Z is halogen or SO 2 R 4 ; R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and R 4 It is C 1 -C 4 alkyl; Treatment in the presence of a second base provides a compound of formula 8 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3.

8. The method according to claim 7, in, R 3 It's chlorine.

9. The method according to claim 7, in, Z is SO 2 R 4 。 10. The method according to claim 9, in, The compound of formula 7 is prepared by the following method: a compound of formula 10 in R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and Q is Cl or OH; Treating in the presence of a halogenating agent and a compound having the formula 11 in R A and R B Each independently is C 1 -C 4 Alkyl; or R A and R B Together for -(CH 2 ) 4 -、-(CH 2 ) 5 -or-CH 2 CH 2 OCH 2 CH 2 - To provide an intermediate having formula 12 in R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and R A and R B Each independently is C 1 -C 4 Alkyl; or R A and R B Together for -(CH 2 ) 4 -、-(CH 2 ) 5 -or-CH 2 CH 2 OCH 2 CH 2 -; and Hal - is a chloride ion or a bromide ion; The intermediate of formula 12 is treated with an acid salt of a compound of formula 13 Where R 4 It is C 1 -C 4 alkyl; Treatment in the presence of a base provides a compound of formula 14 in R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; R 4 It is C 1 -C 4 Alkyl; and The compound of formula 14 is treated with an oxidizing agent.

11. The method according to claim 7, in, The compound of formula 8 is selected from the group consisting of: 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine, 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine, 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine, 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine, 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine, 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine, 5-bromo-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine and 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-bromophenoxy]pyrimidine.

12. The method according to claim 11, in, The compound of formula 8 is a compound of formula 8A 13. A method for preparing a compound having formula 8 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3; The method includes The compound having the formula 2 in Each R 1 are independently halogen; m is 1, 2, or 3; and X is a halogen; Using a compound having formula 3 R 2 (C=O)LG 3 in R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and LG is chlorine, C 1 -C 4 Alkoxy or -O(C=O)R 2 ; Treatment in the presence of a base provides a salt of a compound of formula 4 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; m is 1, 2, or 3; and X is a halogen; Heating the salt of the compound of formula 4 to provide a compound of formula 5 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3; The compound of formula 5 is treated with a hydroxylamine salt to provide a compound of formula 6 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3; The compound of formula 6 is treated with an acid to provide a compound of formula 1 in Each R 1 are independently halogen; R 2 It is cyano, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and m is 1, 2, or 3; and The compound of formula 1 is reacted with a compound of formula 7 in Z is halogen or SO 2 R 4 ; R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; R 4 It is C 1 -C 4 alkyl; The treatment is carried out in the presence of a second base.

14. The method according to claim 13, in, R 2 It is C 1 -C 4 haloalkyl; and m is 1 or 2.

15. The method of claim 14, in, Each R 1 are independently halogen; R 2 It is C 1 -C 2 fluoroalkyl; and R 3 It's a halogen.

16. The method of claim 15, in, R 1 It is a halogen; R 2 It is C 1 Fluoroalkyl; m is 1; and R 1 Attached to the remainder of Formula 1 at the 3-position.

17. The method of claim 16, in, R 1 It is chlorine; R 2 is CHF 2 ;and R 3 It's chlorine.

18. The method of claim 14, in, The compound of formula 2 is prepared by the following method: a compound of formula 9 in Each R 1 are independently halogen; X is a halogen; and m is 1, 2, or 3; Treatment is with methylmagnesium halide followed by water or aqueous acid.

19. The method of claim 13, in, Z is SO 2 R 4 。 20. The method of claim 19, in, The compound of formula 7 is prepared by the following method: a compound of formula 10 in R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and Q is Cl or OH; Treating in the presence of a halogenating agent and a compound having the formula 11 in R A and R B Each independently is C 1 -C 4 Alkyl; or R A and R B Together for -(CH 2 ) 4 -、-(CH 2 ) 5 -or-CH 2 CH 2 OCH 2 CH 2 - To provide an intermediate having formula 12 in R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 haloalkyl; and R A and R B Each independently is C 1 -C 4 Alkyl; or R A and R B Together for -(CH 2 ) 4 -、-(CH 2 ) 5 -or-CH 2 CH 2 OCH 2 CH 2 -;and Hal - is a chloride ion or a bromide ion; The intermediate of formula 12 is treated with an acid salt of a compound of formula 13 Where R 4 It is C 1 -C 4 alkyl Treatment in the presence of a base provides a compound of formula 14 in R 3 Halogen, C 1 -C 4 Alkyl or C 1 -C 4 Haloalkyl; R 4 It is C 1 -C 4 Alkyl; and The compound of formula 14 is treated with an oxidizing agent.

21. The method of claim 13, in, The compound of formula 8 is selected from the group consisting of: 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine, 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine, 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine, 5-chloro-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-fluorophenoxy]pyrimidine, 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine, 5-bromo-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine, 5-bromo-2-[2-[3-(trifluoromethyl)-5-isoxazolyl]-3-chlorophenoxy]pyrimidine and 5-chloro-2-[2-[3-(difluoromethyl)-5-isoxazolyl]-3-bromophenoxy]pyrimidine.

22. The method of claim 21, in, The compound of formula 8 is a compound of formula 8A 23. A method for preparing a compound having formula 5 in Each R 1 are independently halogen; R 2 It is C 1 -C 4 haloalkyl; and m is 1, 2 or 3; the method include: The compound having the formula 2 in Each R 1 are independently halogen; m is 1, 2, or 3; and X is a halogen; Using a compound having formula 3A R 2 (C=O)LG 3A in R 2 It is C 1 -C 4 haloalkyl; and LG is chlorine, C 1 -C 4 Alkoxy or -O(C=O)R 2 ; Treating in the presence of an alkali metal base to provide a compound of formula 4 or an alkali metal salt thereof in Each R 1 are independently halogen; R 2 It is C 1 -C 4 Haloalkyl; m is 1, 2, or 3; and X is halogen; and The compound of Formula 4 or an alkali metal salt thereof is heated.

24. The method of claim 23, in, R 2 It is C 1 -C 2 haloalkyl; and m is 1 or 2.

25. The method of claim 24, in, Each R 1 are independently halogen; and R 2 It is C 1 -C 2 Fluoroalkyl.

26. The method of claim 25, in, R 1 It is a halogen; R 2 It is C 1 Fluoroalkyl; m is 1; and R 1 Attached to the remainder of Formula 1 at the 3-position.

27. The method of claim 26, in, R 1 is chlorine; and R 2 is CHF 2 .

28. A compound having formula 5A in R 1 is a halogen; and R 2 It is C 1 -C 2 Haloalkyl; when R 1 When it is fluorine, R 2 Not trifluoromethyl.

29. The compound according to claim 28, in, R 2 It is C 1 -C 2 Fluoroalkyl.

30. The compound of claim 29, in, R 1 is a halogen; and R 2 It is C 1 Fluoroalkyl.

31. The compound of claim 30, in, R 1 is chlorine; and R 2 is CHF 2 .

32. A compound having formula 4B in R 1 It is a halogen; R 2 It is C 1 -C 2 haloalkyl; and X is a halogen; when R 1 When it is fluorine, R 2 Not trifluoromethyl.

33. The compound of claim 32, in, R 2 It is C 1 -C 2 Fluoroalkyl.

34. The compound of claim 33, in, R 1 is a halogen; and R 2 It is C 1 Fluoroalkyl.

35. The compound of claim 34, in, R 1 is chlorine; and R 2 is CHF 2 .

36. The compound of claim 35, which is the sodium salt of a compound of formula 4C

Citation Information

Patent Citations

  • Pyrimidinyloxy benzene derivatives as herbicides

    WO2015108779A1

  • Synthetic method for chromone compound

    CN102140087A

  • Synthesis method of high-purity o-bromoacetophnones

    CN105523911A

  • Pyrimidinyloxy benzene derivatives as herbicides

    CN105916849A